## Abstract ## Aims Recent retrospective trials stated that a benefit of surgery for recurrent ovarian cancer may be limited to patients in whom a complete cytoreduction (R0) could be achieved. Most of them pointed out there was no difference in survival between residual disease of 0.1–1 cm (R1) a
Secondary cytoreduction for patients with recurrent ovarian cancer
✍ Scribed by Teresa P. Díaz-Montes; Robert E. Bristow
- Book ID
- 107546348
- Publisher
- Current Science Inc.
- Year
- 2005
- Tongue
- English
- Weight
- 419 KB
- Volume
- 7
- Category
- Article
- ISSN
- 1523-3790
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Background. The prognosis for patients with recurrent epithelial ovarian cancer is poor. Most are treated with salvage chemotherapy. The role of secondary cytoreductive surgery is controversial. Hence, this prospective study was undertaken to determine the feasibility and benefit of secondary cytore
## Abstract ## Objective Significant controversy exists concerning the factors affecting survival after secondary cytoreduction (SCR) in recurrent ovarian cancer. This study aims to identify factors independently associated with survival after SCR. ## Methods We retrospectively retrieved 39 pati